Treating diastolic heart failure with AGE crosslink breakers: Thinking outside the heart failure box

Journal of Cardiac Failure

Volumn 11, Issue 3, 2005, Pages 196-199

  Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEUROHORMONE; PEPTIDE HORMONE ANTAGONIST; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AORTA DISEASE; CLINICAL TRIAL; CROSS LINKING; DRUG EFFECT; DRUG EFFICACY; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY INJURY; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 16244385902     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2005.02.001     Document Type: Editorial

References (39)

1. M. Senni, C.M. Tribouilloy, R.J. Rodeheffer, S.J. Jacobsen, J.M. Evans, and K.R. Bailey Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991 Circulation 98 1998 2282 2289
2. R.B. Devereux, M.J. Roman, J.E. Liu, T.K. Welty, E.T. Lee, and R. Rodeheffer Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study Am J Cardiol 86 2000 1090 1096
3. D.W. Kitzman, J.M. Gardin, J.S. Gottdiener, A. Arnold, R. Boineau, and G. Aurigemma Cardiovascular Health Study Research G. Importance of heart failure with preserved systolic function in patients > or =65 years of age. CHS Research Group. Cardiovascular Health Study Am J Cardiol 87 2001 413 419
4. D.W. Kitzman, J.M. Gardin, A. Arnold, J.S. Gottdiener, M.L. Vivienne, and E. Smith Heart failure with preserved LV function in the elderly: clinical and echocardiographic correlates from the cardiovascular health study Circulation 94 1999 I-433
5. R.S. Vasan, M.G. Larson, E.J. Benjamin, J.C. Evans, C.K. Reiss, and D. Levy Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction J Am Coll Cardiol 33 1999 1948 1955
6. R.S. Vasan, E.J. Benjamin, and D. Levy Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective J Am Coll Cardiol 26 1995 1565 1573
7. K. Hogg, K. Swedberg, and J. McMurray Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis J Am Coll Cardiol 43 2004 317 327
8. M.M. Redfield Heart failure - an epidemic of uncertain proportions N Engl J Med 347 2002 1442 1444
9. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group New Engl J Med 446 1997 525 533
10. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J.V. McMurray, and E.L. Michelson Effects of candesartan on morality and morbidity in patients with chronic heart failure: the CHARM-Overall program Lancet 362 2003 759 766
11. M.R. Zile, and D.L. Brutsaert New concepts in diastolic dysfunction and diastolic heart failure: part II - causal mechanisms and treatment Circulation 105 2002 1503 1508
12. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, deGroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Cardiac Fail. In press.
13. M.S. Maurer, M. Packer, and D. Burkhoff Diastolic heart failure N Engl J Med 351 2004 1143 1145
14. M.R. Zile, C.F. Baicu, and W.H. Gaasch Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle N Engl J Med 350 2004 1953 1959
15. H.H. Chen, J.G. Lainchbury, M. Senni, K.R. Bailey, and M.M. Redfield Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria J Card Fail 8 2002 279 287
16. D.W. Kitzman, W.C. Little, P.H. Brubaker, R.T. Anderson, W.G. Hundley, and C.T. Marburger Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure JAMA 288 2002 2144 2150
17. J.G. Lainchbury, E. Campbell, C.M. Frampton, T.G. Yandle, M.G. Nicholls, and A.M. Richards Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath J Am Coll Cardiol 42 2003 728 735
18. H. Yamaguchi, J. Yoshida, K. Yamamoto, Y. Sakata, T. Mano, and N. Akehi Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy J Am Coll Cardiol 43 2004 55 60
19. A.S. Maisel, J. McCord, R.M. Nowak, J.E. Hollander, A.H. Wu, and P. Duc Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study J Am Coll Cardiol 41 2003 2010 2017
20. H. Villacorta, A. Campos, N. Duarte, M.V. Martins, and E.T. Mesquita The utility of B-type natriuretic peptide in the diagnosis of heart failure with preserved systolic function in patients presenting to the emergency department with dyspnea J Card Fail 8 2002 S28
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
22. L.M. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, and G.L. Jennings A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
23. M. Konstam Systolic and diastolic dysfunction in heart failure? Time for a new paradigm J Card Fail 9 2003 1 3
24. M. Kawaguchi, I. Hay, B. Fetics, and D.A. Kass Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction Circulation 107 2003 714 720
25. W.G. Hundley, D.W. Kitzman, T.M. Morgan, C.A. Hamilton, S.N. Darty, and K.P. Stewart Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance J Am Coll Cardiol 38 2001 796 802
26. E.G. Lakatta, and D. Levy Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease Circulation 107 2003 139 146
27. G.F. Mitchell, H. Parise, E.J. Benjamin, M.G. Larson, M.J. Keyes, and J.A. Vita Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study Hypertension 43 2004 1239 1245
28. C.-H. Chen, M. Nakayama, E. Nevo, B. Fetics, W.L. Maughan, and D.A. Kass Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly J Am Coll Cardiol 32 1998 1221 1227
29. T.S. Harris, C.F. Baicu, C.H. Conrad, M. Koide, J.M. Buckley, and M. Barnes Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness Am J Physiol Heart Circ Physiol 282 2002 H2173 H2182
30. D.A. Kass, J.G. Bronzwaer, and W.J. Paulus What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94 2004 1533 1542
31. M.F. O'Rourke Arterial stiffness and hypertension J.L. Izzo H.R. Black Hypertension primer 1999 Lippincott Williams & Wilkins Baltimore 160 162
32. M.E. Safar, B.I. Levy, and H. Struijker-Boudier Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases Circulation 107 2003 2864 2869
33. G.L. Bakris, A.J. Bank, D.A. Kass, J.M. Neutel, R.A. Preston, and S. Oparil Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process Am J Hypertens 17 2004 23S 30S
34. D.A. Kass Getting better without AGE: new insights into the diabetic heart Circ Res 92 2003 704 706
35. A.J. Smit, and H.L. Lutgers The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation Curr Med Chem 11 2004 2767 2784
36. S. Vasan, P.G. Foiles, and H.W. Founds Therapeutic potential of AGE-inhibitors and breakers of AGE-protein crosslinks Expert Opin Investig Drugs 10 2001 1 11
37. M. Asif, J. Egan, S. Vasan, G.N. Jyothirmayi, M.R. Masurekar, and S. Lopez An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness Proc Natl Acad Sci U S A 97 2000 2809 2813
38. P.V. Vaitkevicius, M. Lane, H. Spurgeon, D.K. Ingram, G.S. Roth, and J.J. Egan A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys Proc Natl Acad Sci U S A 98 2001 1171 1175
39. D.A. Kass, E.P. Shapiro, M. Kawaguchi, A.R. Capriotti, A. Scuteri, and R.C. deGroof Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 2001 1464 1470